Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
2
Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada) General Information
Description
Commercial rights of the ATX-101. The asset includes all rights outside of the U.S. and Canada to ATX-101, a proprietary formulation of a purified synthetic version of deoxycholic acid currently in late-stage development for the reduction of submental fat.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Acquirer
Primary Office
- 51368 Leverkusen
- Germany
Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|